Login
About Alexion
Our Leadership
Our Partnerships
Our Ethical Standards
Our History
Patient Focus
Advocacy
Patient Stories
Products
Soliris
®
PNH
aHUS
Strensiq
®
Kanuma
®
Research & Development
Our Pipeline
Development Programs
Investigator-Sponsored Research
Discovery Partnerships
Responsibility
Global Access to Medicines Policy
Main Menu
Careers
Job Opportunities
Why Choose Alexion
Culture
Compensation & Benefits
Work/Life Balance
Health & Wellness
Financial Security
Recognition & Rewards
Personal Growth & Development
Professional Development
Select a Country
North America
Canada
USA
Latin America
Argentina
Brazil
Colombia
Mexico
Europe, the Middle East & Africa
Alexion Europe
Belgium
Denmark
France
Germany
Ireland
Italy
Netherlands
Norway
Russia
Spain
Sweden
Switzerland
Turkey
UAE
UK
Asia Pacific
Australia
China
India
Japan
Investors
News
Contact
Select a Country
Investors
News
Contact
Search for:
North America
Canada
United States
Latin America
Argentina
Brazil
Colombia
Mexico
Europe, the Middle East & Africa
Alexion Europe
Belgium
Denmark
France
Germany
Ireland
Italy
Netherlands
Norway
Russia
Spain
Sweden
Switzerland
Turkey
UAE
United Kingdom
Asia Pacific
Australia
China
India
Japan
About Alexion
Patient Focus
Products
Research & Development
Responsibility
Careers
Select a Country
North America
Canada
USA
Latin America
Argentina
Brazil
Colombia
Mexico
Europe, the Middle East & Africa
Alexion Europe
Belgium
Denmark
France
Germany
Ireland
Italy
Netherlands
Norway
Russia
Spain
Sweden
Switzerland
Turkey
UAE
UK
Asia Pacific
Australia
China
India
Japan
Investors
News
Contact
Home
»
Newsroom
»
Press Releases
»
Product News
Product News
Press Releases
Filter by Category
All Press Releases
Company Releases
Company Statements
Financial Releases
Product Releases
Sort by Year
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
Media
Inquiries
Media
Materials
Email
Alerts
Search Newsroom
New Data Detailing the Devastating Nature of Hypophosphatasia (HPP) and Treatment Effect of Asfotase Alfa in Infants, Young Children and Juveniles with HPP Presented at the Pediatric Academic Societies Meeting
May 5, 2014
HTML
PDF
FDA Approves Conversion of Soliris® (eculizumab) Accelerated Approval in aHUS to Regular Approval for the Treatment of Patients with aHUS
May 5, 2014
HTML
PDF
European Commission Grants Orphan Drug Designation to Soliris® (Eculizumab) for Prevention of Delayed Graft Function (DGF) after Solid Organ Transplantation
February 24, 2014
HTML
PDF
FDA Grants Orphan Drug Designation to Soliris® (eculizumab) for Prevention of Delayed Graft Function (DGF) in Renal Transplant Patients
January 21, 2014
HTML
PDF
Alexion Provides Update on Previously Communicated November 2013 Voluntary Nationwide Recall of Two Lots of Soliris® (eculizumab) Concentrated Solution for Intravenous Infusion
December 13, 2013
HTML
PDF
New Data Presented at ASH Annual Meeting Enhance Understanding of PNH and aHUS to Provide Optimal Care for Patients with These Life-threatening Disorders
December 8, 2013
HTML
PDF
Soliris® (eculizumab) Inhibits TMA and Improves Renal Function in Pediatric and Adult Patients with atypical Hemolytic Uremic Syndrome (aHUS)
November 9, 2013
HTML
PDF
Researchers to Present Clinical Trial Data With Soliris® (eculizumab) Treatment in Both Approved Indications – PNH and aHUS – at ASH Annual Meeting
November 7, 2013
HTML
PDF
FDA Grants Breakthrough Therapy Designation to cPMP Replacement Therapy for Patients with Molybdenum Cofactor Deficiency (MoCD) Type A
October 24, 2013
HTML
PDF
Researchers to Present New Data on Soliris® (eculizumab) as a Treatment for Patients with aHUS at ASN Annual Meeting
October 16, 2013
HTML
PDF
« first
‹ previous
…
3
4
5
6
7
8
9
10
11
…
next ›
last »
